NCT05933577 — intismeran autogene (mRNA-4157) neoantigen vaccine trial
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Intismeran autogene (mRNA-4157 / V940), Moderna + Merck — INTerpath-001 adjuvant melanoma, Phase 3
Registry record
| Registry ID | NCT05933577 ↗ |
|---|---|
| Lead sponsor | Merck Sharp & Dohme LLC |
| Collaborators | ModernaTX, Inc. |
| Phase | Phase 3 |
| Status | Active Not Recruiting |
| Indication | Melanoma |
| Enrollment | 1,089 participants (target) |
| Start date | 2023-07-19 |
| Primary completion | 2029-10-26 (est.) |
| Last registry update | 24 Sept 2025 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT05933577), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT05933577?
NCT05933577 (A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)) is registered on ClinicalTrials.gov as Phase 3, sponsored by Merck Sharp & Dohme LLC.
Is NCT05933577 recruiting?
As of the 2025-09-24 registry update, NCT05933577 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT05933577?
The lead sponsor is Merck Sharp & Dohme LLC. Collaborators: ModernaTX, Inc..
What condition does NCT05933577 study?
The registered condition is Melanoma. Primary completion is listed as 2029-10-26 (estimated).
Are results available for NCT05933577?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT05933577.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.